Company / Free Cash Flow
Beam Therapeutics Inc. Free Cash Flow History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
-$360.0M
FY2025
5-year range
-$360.0M / -$26.4M
FY2021-FY2025
Trend
-1.1%
vs FY2024
Sector context
#176 of 194
Health Care
What the data says
Among 194 Health Care companies, Beam Therapeutics Inc. is in the bottom 9% for free cash flow. Free Cash Flow has declined for 3 consecutive years, from -$26M in FY2022 to -$360M in FY2025.
Based on SEC 10-K filings.
-$360M in FY2025.
Declined from -$183M to -$360M over the past 2 years.
Health Care sector context is included.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 9% in Health CareTop 91% of 194This company -$360.0M Sector average $470.6M
▼
-176.5% below sector average
Key checks
Key Insights
- Beam Therapeutics Inc.'s free cash flow has declined for 3 consecutive years.
- In FY2025, free cash flow decreased 1.1% year-over-year.
- Ranks #176 out of 194 companies in the Health Care sector.
- Peak free cash flow was recorded in FY2022.
Company context
Key Data Points
- Altman Z-Score 1.06 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$360.0M | -1.1% |
| FY2024 | -$356.2M | -94.7% |
| FY2023 | -$182.9M | -592.3% |
| FY2022 | -$26.4M | +76.6% |
| FY2021 | -$113.1M | -33.8% |
| FY2020 | -$84.5M | +0.0% |
| FY2019 | -$84.5M | - |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026